Maintenance therapy for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether continuing an immunotherapy drug (durvalumab or pembrolizumab) alone after initial chemo-immunotherapy is safe and effective for people with advanced bile duct or gallbladder cancer. The goal is to see if this maintenance approach helps keep the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have advanced bile duct or gallbladder cancer that did not get worse after at least 8 cycles of initial treatment with an immunotherapy drug plus gemcitabine and cisplatin.
- You are now scheduled to continue on the immunotherapy drug alone (no more chemo).
- You have at least one tumor that can be measured by scans (RECIST).
- You are in good general health (able to do daily activities – ECOG 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a vaccine-like treatment (OBI-833/OBI-821) after initial chemotherapy can help keep bile duct or gallbladder cancer from growing. If you have a tumor that is stable or improved after gemcitabine and cisplatin, this maintenance therapy might offer a new way to control the disease.
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
This trial tests a combination of two drugs—durvalumab (an immunotherapy) and olaparib (a targeted therapy)—for people with advanced bile duct cancer that did not grow after initial treatment with chemotherapy and durvalumab. The goal is to see if this combination can help control the cancer further.
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.